Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Philippe Rougier; Hanno Riess; Robert Manges; Petr Karásek; Yves Humblet; Carlo Barone; Armando Santoro; Sylvie Assadourian; Laurence Hatteville; Philip Agop Philip

doi:10.1016/j.ejca.2013.04.002

journal article Aug 01, 2013

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Philippe Rougier Hanno Riess Robert Manges Petr Karásek Yves Humblet Carlo Barone Armando Santoro

Sylvie Assadourian Laurence Hatteville Philip Agop Philip

European Journal of Cancer Vol. 49 No. 12 pp. 2633-2642 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2013.04.002

Topics

No keywords indexed for this article. Browse by subject →

References

33

[1]

Ferlay "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008" Int J Cancer (2010) 10.1002/ijc.25516

[2]

Burris "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial" J Clin Oncol (1997) 10.1200/jco.1997.15.6.2403

[3]

Van Cutsem "Lessons learned in the management of advanced pancreatic cancer" J Clin Oncol (2007) 10.1200/jco.2006.09.4664

[4]

Herrmann "Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group" J Clin Oncol (2007) 10.1200/jco.2006.09.0886

[5]

Cunningham "Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer" J Clin Oncol (2009) 10.1200/jco.2009.24.2446

[6]

Dahan "Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)" Gut (2010) 10.1136/gut.2010.216135

[7]

Poplin "Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group" J Clin Oncol (2009) 10.1200/jco.2008.20.9007

[8]

Colucci "Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study" J Clin Oncol (2010) 10.1200/jco.2009.25.4433

[9]

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al.

New England Journal of Medicine 2011 10.1056/nejmoa1011923

[10]

Moore "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group" J Clin Oncol (2007) 10.1200/jco.2006.07.9525

[11]

Philip "Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205" J Clin Oncol (2010) 10.1200/jco.2009.25.7550

[12]

Ferrara "Vascular endothelial growth factor as a target for anticancer therapy" Oncologist (2004) 10.1634/theoncologist.9-suppl_1-2

[13]

Seo "High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma" Cancer (2000) 10.1002/(sici)1097-0142(20000515)88:10<2239::aid-cncr6>3.0.co;2-v

[14]

Itakura "Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression" Clin Cancer Res (1997)

[15]

Baker "Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer" Cancer Res (2002)

[16]

Van Cutsem "Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer" J Clin Oncol (2009) 10.1200/jco.2008.20.0238

[17]

Kindler "Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)" J Clin Oncol (2010) 10.1200/jco.2010.28.1386

[18]

Lau "Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis" Curr Opin Mol Ther (2005)

[19]

Holash "VEGF-Trap: a VEGF blocker with potent antitumor effects" Proc Natl Acad Sci U S A (2002) 10.1073/pnas.172398299

[20]

Fukasawa "Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines" Clin Cancer Res (2004) 10.1158/1078-0432.ccr-03-0820

[21]

Lockhart "Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors" J Clin Oncol (2010) 10.1200/jco.2009.22.9237

[22]

Patnaik "A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results" J Clin Oncol (2008) 10.1200/jco.2008.26.15_suppl.3558

[23]

Hurwitz "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" N Engl J Med (2004) 10.1056/nejmoa032691

[24]

Motzer "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma" J Clin Oncol (2006) 10.1200/jco.2005.02.2574

[25]

Miller "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer" N Engl J Med (2007) 10.1056/nejmoa072113

[26]

Kuo "Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer" Proc Natl Acad Sci U S A (2001) 10.1073/pnas.081615298

[27]

Louvet "Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial" J Clin Oncol (2005) 10.1200/jco.2005.06.023

[28]

Osterlund "Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy" Br J Cancer (2011) 10.1038/bjc.2011.2

[29]

Leighl "A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung" J Thorac Oncol (2010) 10.1097/jto.0b013e3181e2f7fb

[30]

Lu "Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap" Clin Cancer Res (2009) 10.1158/1078-0432.ccr-08-3203

[31]

Kindler "Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study" Lancet Oncol (2011) 10.1016/s1470-2045(11)70004-3

[32]

Philip "Development of targeted therapies for pancreatic cancer" Lancet Oncol (2011) 10.1016/s1470-2045(11)70029-8

[33]

Philip "Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment" J Clin Oncol (2009) 10.1200/jco.2009.21.9022

Cited By

147

Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis

Maki Nishizaki, Yuma Shibutani · 2026

Hypertension Research

Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications

Moritz Reese, Sameer A. Dhayat · 2021

Journal of Hematology & Oncolog...

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

Aleksandra Adamska, Alice Domenichini · 2017

International Journal of Molecular...

Metrics

147

Citations

33

References

Details

Published: Aug 01, 2013
Vol/Issue: 49(12)
Pages: 2633-2642
License: View

Authors

Internistischen Onkologie/Campus Virchow-Klinikum, Charité-Universitätsmedizin, Berlin, Germany

R

Robert Manges

Herbert I. Hurwitz, Duke University Medical Center, Durham, NC; Nikhil Uppal, New York University Langone Arena Oncology, Lake Success, NY; Stephanie A. Wagner, Indiana University Melvin and Bren Simon Cancer Center; Robert Manges, Investigative Clinical Research of Indiana, Indianapolis, IN; Johanna C. Bendell, Sarah Cannon Research Institute, Nashville, TN; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Seaborn M. Wade III, Virginia Cancer Institute, Richmond, VA; John J. Nemunaitis,...

16St-Luc University Hospital, Brussels, Belgium.

C

Carlo Barone

Laboratory for the Interdisciplinary Evaluation of Public Policies (LIEPP), SciencesPo, Paris, France

A

Armando Santoro

Humanitas Research Hospital 11 IRCCS, , Milan, Italy.; 12Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Karmanos Cancer Institute, Detroit, MI

Funding

Sanofi

Cite This Article

Philippe Rougier, Hanno Riess, Robert Manges, et al. (2013). Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European Journal of Cancer, 49(12), 2633-2642. https://doi.org/10.1016/j.ejca.2013.04.002

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

You May Also Like